Auto-antibodies against AngII were developed with SARS-CoV-2 infection

A group from Pritzker School for Molecular Engineering, University of Chicago, Chicago, Illinois, USA, etc. has reported that auto-antibodies against AngII were developed with SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575143/

Surprisingly, it was found that a substantial proportion, 63% (73/115), of the COVID-19 patients had positive levels of anti-AngII autoantibodies, where 115 were hospitalized COVID-19 patients convalescent from a SARS-CoV-2 infection.

First, it was pointed out that the levels of anti-AngII were significantly higher in patients with dysregulated blood pressure as shown below.

Further, the effect of anti-AngII autoantibodies on oximetric saturation (SF ratio) was measured. The lowest daily mean SF ratio was compared between the COVID-19 patients who developed auto-antibodies against AngII (73 patients) and those who did not (42 patients) as shown below.

It was considered that SARS-CoV-2 and AngII to ACE-2 might lead to their co-phagocytosis by antigenpresenting cells, thus providing a strong immune adjuvant (the virus molecules) to the self-peptide AngII, leading to an anti-AngII autoimmune response.